Neonc Technologies Reports New Survival Case in Intranasal NEO100 Trial for Recurrent Astrocytoma

Updated Clinical Trial Results for NEO100

• 💡 Neonc Technologies has announced updated clinical trial data for its intranasal therapy, NEO100.
• 🎯 The therapy is being evaluated in patients with recurrent astrocytoma, a difficult-to-treat CNS cancer.

New Patient Achieves Long-Term Survival and Remission

• 🚀 An additional patient has achieved durable long-term survival and radiographic remission.
• 📈 This new responder further strengthens the observed clinical signal for NEO100.

Expanded Cohort Reinforces Therapeutic Benefit

• 📊 The expanded clinical cohort now includes 25 patients.
• ✅ Findings demonstrate the reproducibility and durability of the therapeutic benefit.
• ⚠️ Importantly, no significant toxicity has been observed to date.

Significance for CNS Oncology

• 🔬 The growing body of evidence for intranasal NEO100 positions Neonc Technologies as an innovator in CNS oncology therapeutic development.
• 🌟 Recurrent astrocytoma has limited effective treatment options, making promising new therapies like NEO100 significant.